Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study was to evaluate the regulatory effects of Huangqian-biobacteria compound preparation on liver health and related metabolic disorders in middle-aged and elderly people, observe its effects on liver function indexes, basal metabolic rate, markers of oxidative stress, inflammatory factors and intestinal microecology, and evaluate the incidence of adverse reactions in subjects during the 3-month intervention period.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Probiotic group | Active Comparator | Intervention group of polygonatum-probiotics complex, take 1 piece (2.0 g) daily |
|
| Placebo group | Placebo Comparator | maltodextrin, take 1 piece (2.0 g) daily |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Probiotic | Dietary Supplement | The experimental phase of the study will last for 3 months, and each subject will be followed up 3 times (month 0, Month 1, Month 2, month 3). |
|
| Measure | Description | Time Frame |
|---|---|---|
| Changes in alanine aminotransferase (ALT) levels | ALT level decline indicates improved liver function, assessed via blood tests. | 3 months |
| Changes in aspartate aminotransferase (AST) levels | AST level decline indicates improved liver function, assessed via blood tests. | 3 months |
| Measure | Description | Time Frame |
|---|---|---|
| Changes in basal metabolic rate | The Mifflin-St Jeor equation was used to evaluate the subject's basal metabolic level, reflecting the body's energy expenditure at rest. | 3 months |
| Metabolic index |
Not provided
Inclusion Criteria:
1. The age of the subjects is 40-80 years old; 2. The subject meets one of the following metabolic disease components: ① abdominal B - ultrasound shows fatty liver or fat infiltration; ② arterial blood pressure is higher than 130/85mmHg, or the subject is on antihypertensive treatment; ③ prediabetes or type 2 diabetes, with fasting blood glucose above 6.1mmol/L; ④ overweight or obesity, with BMI of 24.0kg/m² or more, or male waist circumference of 90cm or more, female waist circumference of 85cm or more, or excessive body fat content and percentage.
-
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Bu Shurui | Contact | 18930809609 | 18930819609@163.com |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D005234 | Fatty Liver |
| ID | Term |
|---|---|
| D008107 | Liver Diseases |
| D004066 | Digestive System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D019936 | Probiotics |
| ID | Term |
|---|---|
| D019587 | Dietary Supplements |
| D005502 | Food |
| D000066888 | Diet, Food, and Nutrition |
| D010829 | Physiological Phenomena |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placbo | Dietary Supplement | The experimental phase of the study will last for 3 months, and each subject will be followed up 3 times (month 0, Month 1, Month 2, month 3). |
|
Blood pressure: Evaluate the effects of the tested product on age-related cardiovascular health and monitor changes in systolic and diastolic blood pressure.
| 3 months |
| Gamma-glutamyltransferase (GGT) | Evaluate the effects of the tested product on liver-related components. GGT: The unit is U/L. | 3 months |
| Total bilirubin (TBil) | Evaluate the effects of the tested product on liver-related components. TBil: Unit: μmol/L. | 3 months |
| Uric acid | Evaluate the effects of the tested product on liver-related components. Uric acid: unit: μmol/L. | 3 months |
| Weight | Evaluate the effects of the tested product on body weight. Weight: Unit: kg. | 3 months |
| BMI (body mass index) | The effects of the product on body mass index were evaluated. BMI: Unit: kg/m². | 3 months |
| Fasting blood glucose | Evaluate the effect of the tested product on blood sugar levels. Fasting blood glucose: the unit is mmol/L. | 3 months |
| Total cholesterol | The effect of the tested product on lipid levels was evaluated. Total cholesterol: Unit: mmol/L. | 3 months |
| Triglyceride | The effect of the tested product on lipid levels was evaluated. Triglyceride: The unit is mmol/L. | 3 months |
| Low-density lipoprotein (LDL) | The effect of the tested product on lipid levels was evaluated. LDL: The unit is mmol/L. | 3 months |
| High density lipoprotein (HDL) | The effect of the tested product on lipid levels was evaluated. HDL: The unit is mmol/L. | 3 months |
| Changes in malondialdehyde (MDA) levels | Evaluate the effects of test products on oxidative stress levels. MDA: The unit is μmol/L. | 3 months |
| Changes in the level of superoxide dismutase (SOD) | Evaluate the effects of test products on oxidative stress levels. SOD: The unit is U/mL. | 3 months |
| Changes in glutathione (GSH) levels | Evaluate the effects of test products on oxidative stress levels. GSH: Unit: μmol/L | 3 months |
| Fatigue Severity Scale (FSS) | Evaluate the fatigue severity of the tested product. FSS score: The unit is points, ranging from 1 to 7 points. 1 score: No fatigue Score 7: Extreme fatigue Higher score: indicates more severe fatigue | 3 months |
| Pittsburgh Sleep Quality Index (PSQI) | Participants' overall sleep quality over the past three months was assessed. PSQI score: The unit is points, ranging from 0 to 21 points. 0 score: Best sleep quality 21 points: worst sleep quality Higher score: indicates poorer sleep quality | 3 months |
| Short-chain fatty acids (SCFAs) | hort-chain fatty acids: Short-chain fatty acids such as acetic acid, propionic acid, and butyric acid are analyzed in stool samples by gas chromatography-mass spectrometry (GC-MS) or high performance liquid chromatography (HPLC). Acetic acid: unit: μmol/g fecal matter. Propionic acid: The unit is μmol/g feces. Butyric acid: The unit is μmol/g feces. | 3 months |
| Fecal flora structure (16S rRNA sequencing) | 16S rRNA sequencing: Bacterial 16S rRNA genes in fecal samples are analyzed by high-throughput sequencing techniques to determine the diversity and composition of the gut microbiota. Diversity index: such as Shannon index, Chao1 index, etc., used to measure the diversity of flora. Composition analysis: The relative abundance of major bacterial phyla, genera and species is determined by taxonomic analysis. | 3 months |
| Inflammatory factor | Changes in serum levels of inflammatory cytokines (IL-6, IL-1β, TNF-α, IP-10) : To evaluate the effect of the tested product on the inflammatory response and reflect the immune status of the body. | 3 months |
| Fatty liver morphology | Abdominal B-ultrasound: To evaluate the effect of the tested product on the morphology of fatty liver, reflecting the liver fat deposition. | 3 months |
| D019602 |
| Food and Beverages |